Clinical Trial Update: Efficacy of Etoricoxib 60 mg in Modifying Pain Hypersensitivity in People With Knee Osteoarthritis [Phase 4]

View source ↗

Summary

This Phase 4 trial evaluated whether etoricoxib 60 mg reduces pain hypersensitivity in individuals with knee osteoarthritis. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis

Drugs mentioned

• Etoricoxib (etoricoxib)

Snippet

Sponsor: Curtin University | Conditions: Osteoarthritis, Pain | Phase 4 | Status: COMPLETED